ACP set to buy into graphite buzz

|

Published 21-JUN-2016 11:11 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Armadale Capital (AIM:ACP) say it will more than likely take its place in the Tanzanian graphite game after rock chip samples came back at grades of up to 33.8% at Liandu.

The London-listed company told its shareholders overnight that it had taken rock chip samples, with some focusing on the sites of previous drilling which had struck graphite interceptions including:

  • 60m @ 10.7 total graphitic content (TGC) from surface, including 12.9% TGC and 5m @ 21.5TGC.

It took a raft of rock chip samples from graphitic schists at the project, with samples ranging from 1.22% to 33.8% TGC.

The average from the samples was 12.8% TGC.

In addition, four samples were taken from within the existing drillholes, with the rock chips taken from the four samples.

Results largely confirmed what the previous drilling brought up, with only minor variances recorded.

Table showing chip samples against original holes

Table showing chip samples against original holes

On the back of the sampling, ACP said it had largely finished its due diligence on the project and now “anticipates entering into a binding agreement...shortly”.

It entered into a heads of agreement arrangement to acquire the Liandu project earlier this month, hoping to catch the wave of graphite buzz which has weaved its way through the Australian market.

The project itself is next door to Black Rock Mining’s (ASX:BKT) Mahenge project, which has a resource of 131 million tonnes @ 7.9% TGC.

In other news, it said its Mpokoto gold project was closer to funding, with potential funding partner A-MCS continuing to review a definitive feasibility study on the play.

On Armadale Capital and Liandu

Mahenge Liandu Project, which consists of two tenements covering 29.9 km2, adjacent to the town of Mahenge.

A map showing ACP's project

A map showing ACP’s project

In addition to the BKT connection, the project is right next door to Kibaran Resources’ (ASX:KLN) Epanko Project, with a bankable feasibility study done in 2015 finding the project had proven and probable ore reservers of 10.9Mt @ 8.6% TGC.

Initial exploration on ACP’s tenements indicated grades of between 13% to 24% TGC.

Reconnaissance mapping done late last year defined a mineralized trend more than 1.5 km in strike length and up to 500m in width.

From this initial mapping, ACP has been able to obtain some initial drill hole data as an indicator of future potential.

Three RC drill holes drilled late last year by the previous vendors showed intercepts of 24m @ 12.9% TGC, 5m @ 21.5% TGC and 10m @ 6.54% TGC.

Editor’s note – It should be noted that Tanzania is a high risk region owing to political instability which can affect mining projects getting off the ground.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X